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AbstrACt
Introduction Parkinson’s disease is the second most 
common chronic neurodegenerative condition with bladder 
dysfunction affecting up to 71%. Symptoms affect quality 
of life and include urgency, frequency, hesitancy, nocturia 
and incontinence. Addressing urinary dysfunction is one of 
the top 10 priority research areas identified by the James 
Lind Alliance and Parkinson’s UK.
Objectives Conduct a randomised controlled trial (RCT) 
targeting people with Parkinson’s disease (PwP) who have 
self- reported problematic lower urinary tract symptoms, 
investigating the effectiveness of transcutaneous tibial 
nerve stimulation (TTNS) compared with sham TTNS. 
Implement a standardised training approach and package 
for the correct application of TTNS. Conduct a cost- 
effectiveness analysis of TTNS compared with sham TTNS.
Methods and analysis An RCT of 6 weeks with twice 
weekly TTNS or sham TTNS. Participants will be recruited 
in 12 National Health Service neurology/movement 
disorder services, using a web- based randomisation 
system, and will be shown how to apply TTNS or sham 
TTNS. Participants will receive a weekly telephone call 
from the researchers during the intervention period. The 
trial has two coprimary outcome measures: International 
Consultation on Incontinence Questionnaire- Urinary 
Incontinence Short Form and the International Prostate 
Symptom Score. Secondary outcomes include a 3- day 
bladder diary, quality of life, acceptability and fidelity and 
health economic evaluation. Outcomes will be measured at 
0, 6 and 12 weeks.
A sample size of 208 randomised in equal numbers to the 
two arms will provide 90% power to detect a clinically 
important difference of 2.52 points on the Internatioanl 
Consultation on Incontinence Questionnaire - Short Form 
(ICIQ- SF) and of 3 points in the International Prostate 
Symptom Score total score at 12 weeks at 5% significance 
level, based on an SD of 4.7 in each arm and 20% attrition 
at 6 weeks. Analysis will be by intention to treat and pre 
defined in a statistical analysis plan
Ethics and dissemination East of Scotland Research 
Ethics Service (EoSRES), 18/ES00042, obtained on 
10 May 2018. The trial will allow us to determine 
effectiveness, safety, cost and acceptability of TTNS for 
bladder dysfunction in PWP. Results will be published 
in open access journals; lay reports will be posted to all 
participants and presented at conferences.
trial registration number ISRCTN12437878; Pre- results.
IntrOduCtIOn: bACkgrOund And rAtIOnAlE
lower urinary tract (lut) symptoms in 
Parkinson’s disease
Parkinson’s disease is characterised predom-
inantly by the motor complaints of brady-
kinesia, rigidity, rest tremor and gait 
disturbances. However, non- motor symp-
toms (NMS) are a common accompaniment1 
with LUT symptoms reported in 38%–71% 
of people with Parkinson’s disease (PwP).2 
These LUT symptoms are an important 
cause of morbidity and have a major impact 
on early institutionalisation and health- 
related costs.3 There also exists an association 
between nocturia and the risk for falls and 
hip fractures.4–7
Current treatments for LUT dysfunction 
in PwP are limited. It is likely that levodopa 
and other Parkinson’s medication affect 
bladder function; however, studies evaluating 
the effects of these medications on mictu-
rition have produced conflicting results.8 
Currently, PwP may be offered advice on 
fluid intake and on behavioural treatment 
such as habit training or timed voiding with 
or without pelvic floor muscle training, 
strengths and limitations of this study
 ► Fully powered randomised controlled study.
 ► Participants may become unblinded.
 ► Participants may want to switch arms.
by copyright.
 o
n
 February 26, 2020 at University of East Anglia. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034887 on 17 February 2020. Downloaded from 
2 McClurg D, et al. BMJ Open 2020;10:e034887. doi:10.1136/bmjopen-2019-034887
Open access 
but the evidence base supporting these techniques is 
limited.9–13 Antimuscarinic medication, competitively 
antagonise muscarinic acetylcholine receptors, resulting 
in detrusor relaxation, lower intravesical pressures and 
reduced storage symptoms. However, it has been found 
that PwP often discontinue their use due to side effects of 
nausea, dry mouth and constipation.11 More importantly, 
there is evidence to suggest a worsening in cognition and 
consciousness in susceptible neurological patients, and 
caution in prescribing is advised.10 14 Intravesical injec-
tions of botulinum toxin into the detrusor is sometimes 
considered in PwP and has been described in four small 
studies to date,15–18 which reported some improvement in 
symptoms.
For the reasons discussed, there is a need to explore 
options that are non- invasive and associated with minimal 
side effects.
Patient involvement
A focus group of patients and carers of PwP and clini-
cians involved in treatment was held in London in 2017. 
During this meeting, the impact of bladder dysfunction 
on quality of life (QOL) was highlighted and also the lack 
of effective interventions. Transcutaneous tibial nerve 
stimulation (TTNS) was identified as a treatment option 
they would be willing to use, and a treatment regimen of 
twice weekly stimulation sessions for 6 weeks was preferred 
from the point of view of compliance, acceptability and 
practicability. We also have PwP on our trial steering 
committee, and they have advised us on the content of 
our participant facing literature and protocol.
tibial nerve stimulation (tns): a form of neuromodulation
Neuromodulation has been used increasingly to treat 
urinary disorders through stimulation of the sacral, 
pudendal, tibial and genital nerves. The most often 
studied neuromodulation routes for overactive bladder 
(OAB) have been the sacral nerve roots and the tibial 
nerve (TN).17 Nerve fibres in the TN represent the L4- S3 
spinal segments and therefore share a similar origin as 
the innervation to the bladder, rectum, anal sphincter 
and pelvic floor.19 The precise mechanism of action of 
neuromodulation is unclear, but it is thought to modu-
late the sacral plexus indirectly via the sensory, motor and 
autonomic fibres of the TN.19 Percutaneous TNS (PTNS) 
stimulation involves a qualified healthcare provider 
inserting a small needle just behind the medial malleolus 
to conduct the current from the small hand held stim-
ulator. This is a ‘minimally’ invasive neuromodulation 
technique that is recommended by National Institute 
for Health and Care Excellence (NICE)19 for the treat-
ment of OAB symptoms when conservative options have 
failed and is increasingly offered in hospital and urology 
services, requiring the patient to come into clinic for each 
treatment session (usually 12 weekly sessions). In compar-
ison, much less is known about the effects of TTNS using 
the non- invasive transcutaneous route, which involves the 
delivery of the stimulation using surface electrodes that 
can be applied by the patient themselves and that can 
be used in the person’s home. TTNS is potentially more 
accessible and may enable PwP to self- manage and feel 
more in control of their care. It is also less costly than 
other stimulation modalities.
Evidence
As stated above, TNS is a form of peripheral neuromod-
ulation targeted towards symptom relief of OAB and 
urge urinary incontinence.20 The authors reviewed the 
literature relating to the use of TTNS or PTNS in the 
neurogenic population and identified one study with 
spinal cord patients in which the use of TTNS (n=50) was 
compared with solifenacin succinate (n=50). Both groups 
improved significantly in all bladder diary measurements, 
but there were fewer side effects with TTNS.21 Seth et 
al22 compared two different regimens of TTNS (Gp1: 30 
min daily; Gp2: 30 min weekly, for 12 weeks) between 24 
patients with multiple sclerosis (PwMS) with OAB to 24 
people with idiopathic OAB. Significant improvements 
in symptoms were reported for both groups. Another 
prospective study looked at TTNS in 70 PwMS with OAB 
over a 3- month period demonstrating efficacy of reduced 
urinary urgency and frequency as well as other secondary 
outcomes such as improved QOL and reduced burden.23 
Several studies have reported TTNS use to be safe, accept-
able and potentially beneficial in regards to LUT symp-
toms in PwMS in their own homes, older adults in care 
homes and stroke patients in their own homes,22 24 25 
respectively. More recently, a study with 68 participants 
with overactive detrusor persisting after first- line or 
second- line treatments in a non- superiority trial reported 
no difference in efficacy between PTSN and TTNS.26
Studies specific to PwP and PTNS or TTNS are limited. 
Kabay et al27 reported on a non- randomised study with 
47 PwP and PTNS and found significant improvement in 
symptoms and urodynamic parameters. Only two small 
studies were identified with PwP using TTNS.28 29 Ohan-
nessian et al28 demonstrated that five out of six female PwP 
with OAB, who used TTNS for 6 weeks, considered TTNS 
to be effective. The study also implied that TTNS has 
potential efficacy of improving urodynamic and symptom 
scores in this population. Perissinotto et al29 reported a 
study comparing TTNS and placebo stimulation in 13 
PwP presenting with LUT symptoms. They demonstrated 
that TTNS holds promise as an option in the treatment of 
LUT symptoms in this population reducing urgency and 
nocturia and improving QOL.
The findings of this review have identified that TNS 
using the transcutaneous route (TTNS) is a feasible 
option for PwP, but efficacy has not been determined. A 
study is currently underway in France evaluating a TTNS 
regimen of 20 min daily stimulation for 90 days in a mixed 
group of patients with Parkinson’s disease and multiple 
system atrophy (MSA)30 Liaising with the Principle Inves-
tigator, recruitment into the study appears to be satisfac-
tory. Considering that LUT dysfunction in Parkinson’s 
disease and MSA is distinctly dissimilar, we have chosen 
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Table 1 Administrative information
Trial registration with registry that 
adheres to WHO trial registration 
data set
ISRCTN12437878 https://doi.org/10.1186/ISRCTN12437878
Protocol version Version 3 08/10/2019.
Funding This study is supported by a grant from The Dunhill Medical Trust. Parkinson’s UK have 
provided additional support to cover NHS Support Costs.
Name and contact information for the 
trial sponsor
Yasmin Glover, RIE, Glasgow Caledonian University, Cowcaddens Road, Glasgow, G4 
0BA, UK.
Role of sponsor Glasgow Caledonian University is the sponsor and has the responsibility for overseeing 
the management and arranging the finance of the research. It must satisfy itself that the 
study meets the relevant standards and ensure that arrangements are put and kept in 
place for management, monitoring and reporting.
Corresponding author Doreen.mcclurg@gcu.ac.uk
Reporting checklist SPIRIT reporting guidelines were used to complete this protocol publication
Chan A- W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža- Jerić K, 
Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, 
Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: 
Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207.
Author conflicts of interest No conflicts have been declared.
NHS, National Health Service.
to study the effects of TTNS in Parkinson’s disease alone. 
Patient notes will be screened if the diagnosis is unclear. 
In addition, our consultation group of PwP and carers 
unanimously preferred a treatment regimen of twice 
weekly stimulation sessions for 6 weeks rather than daily 
sessions over 3 months from the point of compliance, 
acceptability and practicability. For this reason, we will 
investigate the most commonly used and evaluated treat-
ment protocol for TNS involving 12×30 min stimulation 
sessions over 6 weeks.
It is hypothesised that the effectiveness and cost- 
effectiveness of a strategy of TTNS is superior to sham 
TTNS at 12 weeks.
Objectives
The Stimulation of the tibail nerve for urinary inconti-
nence in Parkinson's (STARTUP) trial will determine/
undertake the following:
1. Conduct a randomised controlled trial (RCT) tar-
geting PwP who have self- reported problematic LUT 
symptoms, investigating the effectiveness of TTNS 
compared with sham TTNS.
2. Implement a standardised training approach and 
package (already developed) for the correct applica-
tion of TTNS.
3. Conduct a cost- effectiveness analysis of TTNS com-
pared with sham TTNS.
4. Assess fidelity to the TTNS intervention and any re-
search participation effects in the intervention and 
placebo stimulation groups.
trial design
The present study is a multicentred, parallel group, supe-
riority, double- blind RCT comparing the effectiveness 
of an experimental strategy of twice weekly use of active 
TTNS for 6 weeks against a twice weekly use of sham 
TTNS for 6 weeks in PwP and LUT symptoms. Randomis-
ation is at a 1:1 ratio for the two arms of the trial.
MEthOds: PArtICIPAnts, IntErvEntIOns And OutCOMEs
Full administrative information is provided in table 1
study setting
Routine care setting for Parkinson’s patients in the UK.
Eligibility criteria
Inclusion criteria
 ► Patients of 18 years of age and above (no upper age 
limit), with a diagnosis of Parkinson’s diesase(any 
stage) with self- reported problematic LUT symptoms.
 ► Capacity to consent/complete self- report outcome 
measures: ability to apply TTNS (or placebo) inde-
pendently or has carer who can apply for duration
 ► Stable Parkinson’s medication for 3 months.
 ► Participants may be treatment naïve, failed or contin-
uing treatment with antimuscarinic medication 
(group allocation will be minimised to account for 
these groups).
 ► Patients who are being treated, or have been treated, 
for benign prostatic hyperplasia or prostate cancer 
can be included at the discretion of the PI.
 ► Patients taking medications such as alpha- blocker 
medicines (prazosin, indoramin, tamsulosin, alfu-
zosin, doxazosin and terazosin), or 5- alpha reduc-
tase inhibitor medicines. Finasteride and dutasteride 
can be included. Patients taking approved treatment 
for prostate cancer, or example, apalutamide and 
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Table 2 Summary of data collection
Baseline
(week 0)
Week 6–7 (on 
completion of 
intervention period
Week 
12
ICIQ- UI SF × × ×
IPSS × × ×
3- day (24 
hours) bladder 
frequency chart
× × ×
Qualiveen × × ×
PDQ-8 × × ×
Resource 
questionnaire
  × ×
Change in 
medication
Weekly ×
Exit 
questionnaire
  ×   
Compliance 
downloaded
  ×   
ICIQ- UI SF, International Consultation on Incontinence 
Questionnaire- Urinary Incontinence Short Form; IPSS, International 
Prostate Symptom Score; PDQ-8, Parkinson’s Disease 
Questionnaire-8 items.
enzalutamide, bicalutamide, Casodex, Zytiga, Lupron 
Depot, Xtandi and Zoladex can be included at the 
discretion of the PI.
 ► Patients who have had or are having treatment for 
cancer, for example, urological cancer can be included 
on an individual basis at the discretion of the PI.
Exclusion criteria
 ► Pacemaker or implanted electrical device, including 
deep brain stimulation.
 ► Unable to understand the instructions relating to the 
bladder diary and/or the use of the stimulator or does 
not have a relative willing to help.
 ► Ulceration or broken skin, in area of pad placement.
 ► History of peripheral vascular disease and epilepsy.
 ► Current urinary tract infection (if suspected by symp-
toms refer to General Practitioner and can recruit 
once cleared).
 ► Receipt of botox for bladder symptoms or TTNS 
within the last year.
Who will take informed consent?
All participants will undergo a process of informed 
consent that will include the delivery of balanced written 
information concerning the need and overall benefit of 
the trial followed up by discussion with a local STARTUP 
researcher. This discussion will include a check of under-
standing concerning benefits and risks of participation 
and ensuring that participants accept that the treatment 
will be allocated at random regardless of any personal 
preference they may have.
Please see online supplementary material to review the 
consent form.
Additional consent provisions for collection and use of 
participant data and biological specimens
Not applicable.
thE IntErvEntIOn
There is a risk of participant unblinding if the interven-
tion or sham intervention is discussed in detail within this 
protocol; this will be published before trial recruitment is 
complete. The authors recognise the importance of the 
allocated intervention being accepted by the participant 
as the active intervention and have developed the sham 
intervention to be as realistic as possible yet delivering no 
intervention.
The treatment protocol developed by Amarenco et al31 
will be adopted for this trial.
All participants will use the stimulator for two 30 min 
sessions a week for 6 weeks. It is preferable to have 2–4 
days between stimulation sessions.
A training protocol, including a manual for clinicians 
and instruction leaflets for participants, has been devel-
oped. Participants will be instructed to use the TTNS 
device twice weekly for 6 weeks with weekly telephone 
support by research staff.
Criteria for discontinuing or modifying allocated interventions
There are no special criteria for discontinuing or modi-
fying allocated interventions. Participants may choose to 
stop doing the active or sham TTNS themselves for any 
reason.
strategies to improve adherence to interventions
None beyond normal encouragement.
relevant concomitant care permitted or prohibited during the 
trial
No special provisions.
Provisions for post-trial care
None beyond standard care within the National Health 
Service (NHS). Agreed to show how to set the parameters 
should the participants want to buy a unit.
Outcomes
The outcome measures and other data to be collected are 
summarised in table 2.
To decrease burden on participants (ie, only one visit), 
the baseline outcome data will be collected at the visit to 
clinic/home following completion of consent, randomis-
ation and instruction on use of device.
Primary outcome measure
The trial has two coprimary outcome measures: Inter-
national Consultation on Incontinence Questionnaire- 
Urinary Incontinence Short Form (ICIQ- UI SF)32 and the 
International Prostate Symptom Score (IPSS).33
These outcomes measure leakage (ICIQ- UI SF) and 
bladder over activity (IPSS) and were used to determine 
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box 1 the participant pathway
Participant’s identified at clinic by local PIs, Parkinson’s nurses or re-
search nurses.
  
Participant information leaflet with expression of interest form attached 
given/sent to patient along with preaddressed envelope.
  
Posters also to be put up in relevant clinics to inform patients.
Potential participants opt in either by phoning the trial office or by re-
turning the expression of interest form to them.
  
Staff at the trial office contact participant discuss further the implica-
tions of the study and complete screening log. If willing and eligible to 
be a participant, then the patient is allocated a participant study number 
and is given an appointment to attend the clinic or for the research 
nurse to visit them at home (confirmed by trial office with clinic)
  
At the clinic/home, the participant will be consented, the clinical assess-
ment form will be completed, randomisation will be completed (using 
the web- based system) and then the participant will be shown how 
to use the stimulation/placebo stimulation and provided with written 
instructions.
  
The participant is given a pack to take home with them containing 
the 3- day bladder frequency diary (with simple instructions) and the 
questionnaire booklet. The participant is asked to complete the bladder 
frequency diary during the next 3 days (starting with the first morning 
void) before starting to use the stimulation. The pack also contains the 
bladder diary and a questionnaire booklet to be completed at 6 weeks. 
Prepaid addressed envelopes will be available.
  
During the 3 days at home, the research office telephones the partici-
pant to support completion of their bladder diary. The participant either 
completes the questionnaires themselves or over the telephone. These 
diaries are then posted to the research office. Date when the participant 
will start using the intervention agreed and the times of the weekly 
follow- up telephone calls agreed.
  
Trial office staff will telephone the participant weekly to see how things 
are going, ask about change in medications, adverse events and so on 
and will be available for any queries. Trial office will remind/help partici-
pant to complete the diary and questionnaires at the end of 6 weeks and 
will get the participant to unlock the compliance monitor before sending 
the unit back in the prepaid Jiffy bag.
  
Trial office staff will post all the 12- week outcome questionnaires to the 
participant and telephone them to help with completion/complete over 
the phone depending on the participant’s preferences.
our sample size. They are validated for use in men and 
women.
The ICIQ- UI SF provides a brief and robust measure to 
assess the impact of symptoms of incontinence on QOL 
and outcome of treatment. It consists of four questions 
measuring frequency of UI, amount of leakage, overall 
impact of UI and when leakage occurs. It has grade A for 
validity, reliability and responsiveness to change estab-
lished with rigour on one data set. The total score ranges 
from 0 to 21 with higher values indicating increased 
severity of symptoms.32
The IPSS is based on the answers to seven questions 
concerning urinary symptoms. The questions refer to the 
following urinary symptoms: (1) incomplete emptying; 
(2) frequency; (3) intermittency; (4) urgency; (5) weak 
stream; (6) straining; and (7) nocturia. Question 8 refers 
to the patient’s perceived QOL. Each question is assigned 
points from 0 to 5 indicating increasing severity of the 
particular symptom. The total score ranges from 0 to 35 
(asymptomatic to very symptomatic). Although there are 
presently no standard recommendations for categorising 
the IPSS score, patients can be tentatively classified as 
follows: 0–7=mildly symptomatic; 8–19=moderately symp-
tomatic; 20–35=severely symptomatic.33
Secondary outcome measures
I. Qualiveen is an eight- item self- administered urinary 
QOL questionnaire validated in the neurogenic 
populations.34
II. Parkinson’s Disease Questionnaire-8 (PDQ-8) is a 
validated eight- item self- administered questionnaire 
measuring Parkinson’s specific QOL.35
III. A 72- hour bladder diary will be completed by par-
ticipants during the week postrandomisation before 
commencing the use of the device at home (week 
0), during week 7 and week 11 and will record fre-
quency of micturition, leakage episodes and urgen-
cy. Participants will be advised to start the diary in 
the morning (first void of that day) following their 
clinic visit.
IV. Compliance: the stimulation unit will record how of-
ten and for how long the participant has used the 
unit during the 6 weeks of intervention, and data will 
be downloaded at clinic on receipt of the unit. The 
units are locked so that it is not possible for the par-
ticipants to change settings or delete data.
V. Resource use questionnaire completed by the partic-
ipant at 6 and 12 weeks will monitor visits to the doc-
tor/nurse/hospital, medications bought/prescribed 
or non- prescribed and purchases such as pads.
VI. Participant experience and protocol fidelity will be 
assessed at 6 weeks in a brief exit questionnaire.
Questionnaires and bladder diaries to be completed 
at 6 weeks will be given to the participant at visit 1, and 
those at 12 weeks will be posted to participants. All will 
be returned to the trial office in reply- paid envelopes. 
Should participants request, completion of the question-
naires may be done verbally by telephone.
Participant timeline/pathway
The steps within the trial that the participants will take 
are summarised in box 1.
sample size calculation
A sample size of 208 participants randomised equally to 
the two arms will provide 90% power to detect a clinically 
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important difference of 2.52 points36 on the primary 
outcome (ICIQ- UI- SF total score) at 6 weeks postrando-
misation, using an independent samples t- test (two- sided 
significance level of 5%), based on an SD of 5 (equating 
to a standardised effect size of 0.5) and an attrition rate of 
20% at 6 weeks. The SD of 5 is based on a recent system-
atic review of TTNS for OAB,37 where two trials reported 
ICIQ- UI- SF as an outcome measure, both with an SD of 
4.3.25 38
For the coprimary outcome measure, the IPSS, the 
minimum clinically important difference is estimated to 
be 3 points33 39 and the systematic review of TTNS iden-
tified a single trial reporting IPSS, where the SD was 4.40 
However, given the limited evidence available, we conser-
vatively assume an SD of 6 points, which equates to a 
standardised effect size of 0.5. Therefore, a sample size 
of 208 will also provide 90% power to detect a clinically 
important difference in the IPSS.
rECruItMEnt
The research team at each study centre will be respon-
sible for identifying potential participants and patients 
can self- refer in response to adverts by Parkinson’s UK 
and contact via patient research registers. Following the 
receipt of an expression of interest, a member of the 
research team will contact the patient by telephone to 
provide further information, assess eligibility and forward 
contact details to the relevant site.
Assignment of interventions: allocation
Sequence generation
Participants who provide written informed consent will be 
randomised using a computer generated system to either 
TTNS intervention or non- active stimulation arm and 
will be minimised on two factors: (1) severity of urinary 
symptoms, as reported at study baseline by the IPSS in 
the Clinical Assessment Form, that is, mild, moderate or 
severe; and (2) status on antimuscarinic medication, that 
is, treatment naïve, failed or continuing such treatment.
Concealment mechanism
A web- based randomisation system will be used.
Implementation
Implementation will be by staff at the Centre for Health-
care Randomised Controlled trials Clinical Trials Unit 
(CTU) at Aberdeen.
Assignment of interventions: blinding
Who will be blinded
Due to the nature of the intervention, the research team 
delivering the intervention will not be blinded to the 
treatment received; however, we have designed several 
different mechanisms by which participant allocation will 
be concealed. Participants will be blinded to group alloca-
tion. Outcome measures are primarily self- reported and 
submitted anonymously. Those involved in the data anal-
yses and statistics will be blinded to the group allocation.
Procedure for unblinding if needed
Clinical staff are not blinded. At 6 weeks, the participant 
will be asked to which group they thought they had been 
allocated to assess the success of blinding. Data will be 
analysed by a statistician who is blinded to group alloca-
tion. At this stage, it they so wish, participants will be told 
to which group they had been assigned.
data collection and management
Plans for assessment and collection of outcomes
Data will be collected via participant- completed question-
naires at baseline and at 6 and 12 weeks. A 3- day bladder 
frequency diary will be completed prior to baseline, at 6 
and 12 weeks. Completed outcome data are retuned by 
post. Relevant demographic and medical history informa-
tion will be collected at baseline.
Patient resource use questionnaires will also be 
completed by participant at home at 6 and 12 weeks.
Plans to promote participant retention and complete follow-up
Nothing beyond normal encouragement to continue to 
use as prescribed. All participants will be offered help 
with setting the parameters of a stimulation unit should 
they purchase one.
data management
All trial participants are given a unique identifying trial 
number that will be used on all case report forms for 
that participant. Data will be entered into the secure trial 
database by the data coordinator based at the STARTUP 
central office at Glasgow Caledonian University.
Confidentiality
All investigators and study centre staff involved with this 
trial will comply with the requirements of the General 
Data Protection Regulations and the Data Protection Act 
2018 in regards to the collection, storage, processing and 
disclosure of personal information.
Data collected during the course of the research is kept 
strictly confidential and accessed only by members of the 
trial team and may be looked at by individuals from the 
sponsor organisation or NHS sites where it is relevant to 
the participant taking part in this trial.
Plans for collection, laboratory evaluation and storage of biological 
specimens for genetic or molecular analysis in this trial/future use
None.
Access to data
All data requests should be submitted to the corre-
sponding author for consideration. Access to anonymised 
data may be granted following review.
AnAlysIs
All analyses will be clearly predefined, in agreed statistical 
and economic analysis plans, to avoid bias. Following data 
lock, analyses will be undertaken before unblinding of 
group allocation takes place. Analyses will be conducted 
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according to the intention- to- treat principle, whereby all 
participants with follow- up data will be analysed according 
to their randomised allocation. A single main analysis will 
be performed at the end of the trial when all follow- up 
has been completed.
Analysis of primary outcome measures
The analysis of the coprimary outcomes (ICIQ- UI SF score 
and IPSS score)32 33 will estimate the mean difference 
(and 95% CIs) between the experimental and compar-
ator arms at 12 weeks postintervention using linear mixed 
models adjusting for minimisation covariates (reported 
symptom severity and treatment category), baseline 
ICIQ- UI SF/IPSS score and other potentially important 
prognostic covariates. Recruiting centre will be included 
in the models as a random effect.
Analysis of secondary outcome measures
Secondary outcomes will be analysed in a similar manner 
using appropriate generalised linear models. Linear 
mixed models will be used to analyse Qualiveen and 
PDQ-8, along with the primary outcomes measures taken 
at 6 weeks. Bladder diary data will be used to analyse 
frequency (using oisson regression) and nocturia (using 
binary logistic regression).
Interim analyses
No interim analyses are planned.
Additional analyses
Subgroup analysis
Subgroup analyses will be carried out on reported 
symptom severity and treatment category. Stricter levels of 
statistical significance (p<0.01) will be sought, reflecting 
the exploratory nature of these analyses.
Economic analysis
The economic analysis will be a within trial evaluation to 
estimate the cost- effectiveness of TTNS compared with 
sham TTNS. This evaluation will be conducted from a UK 
NHS perspective.
The resources required to provide the TTNS treat-
ment will be recorded by the researchers: this will include 
equipment costs; staff time; training required; and 
consumables. Participants will complete simple resource 
use questionnaires at 6 weeks and 12 weeks to record 
relevant healthcare resource use. Costs will be attached to 
resource use using appropriate local or national unit cost 
data, including the Personal and Social Sciences Research 
Unit41 and NHS Reference Costs.42 This will demonstrate 
likely costs of providing TTNS and show key drivers of 
costs for PwP. Medication will also be recorded at these 
time points and costs attached using the British National 
Formulary.43
The resource use data will be combined with the copri-
mary outcome measures in a cost- effectiveness analysis. 
The results will be presented as a mean incremental cost 
per unit change in the ICIQ- UI SF and the mean incre-
mental cost per unit change in the IPSS.
Methods to handle protocol non-adherence and missing data
The analysis will be intention to treat with no account 
taken of protocol non- adherence. Non- compliance to 
randomised allocation is not anticipated as participants 
are blinded throughout.
The extent of missing data will be explored in the 
outcomes, especially the primary outcomes. Patterns of 
missing data will be explored and predictors of missing-
ness examined, especially if these vary by intervention. 
If necessary, multiple imputation will be used to impute 
missing data assuming the missingness mechanism is 
missing at random. A detailed statistical analysis plan will 
be agreed to before the end of data entry and before the 
treatment code is broken.
Plans to give access to the full protocol, participant-level data 
and statistical code
This document is the full protocol. Anyone interested in 
other data or documentation should contact the corre-
sponding author.
Oversight and monitoring
Composition of the coordinating centre and Trial Steering 
Committee
The Trial Management Group consisting of the trial 
manager, admin staff, Chief Investigator and statistician 
will meet on a biweekly basis to discuss progress and 
monitor recruitment, data returns and so on.
The TSC will act as the oversight body for the STARTUP 
trial on behalf of the sponsor and funders. The group will, 
through regular reports, be responsible for monitoring 
recruitment and retention rates and patient safety. They 
will also advise on future continuation of the trial as well 
as modifying target recruitment or pre analysis follow- up, 
based on any change to the assumptions underlying the 
original trial sample size calculation (but not on any 
emerging differences).
The group will also oversee the timely completion of 
the final report and appropriate dissemination. A chair 
with experience of rehabilitation research has been 
appointed, and the group also has a statistician, Patient 
and Public Involvement and a clinically experienced 
person.
Composition of the data monitoring committee, its role and 
reporting structure
It was not felt necessary to have a data monitoring 
committee in this study for a number of reasons: involves 
non- critical indication; low risk of harm to patients; and 
treatment is already available.
Adverse event (AE) reporting and harms
The STARTUP trial involves treatments that are well 
established in clinical practice; therefore, AEs (although 
these are unlikely) will be those observed in everyday 
practice associated with the condition. Expected AEs 
arising from the treatments are noted below and thus will 
not be collected as AEs but noted in the weekly follow- up 
data collection.
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Urinary tract infection
All AEs and serious AEs will be assessed for seriousness, 
causality, severity and expectedness and will be reported 
to the relevant regulatory bodies.
Frequency and plans for auditing trial conduct
The TSC will meet every 6 months.
Ethics and dissemination
The study is sponsored by Glasgow Caledonian University, 
and the START- UP trial office is based in the Nursing, 
Midwifery and Allied Health Professions Research Unit.
Participants have the right to withdraw from the study 
at any time and for any reason, and all participants are 
made aware that withdrawal will not affect their routine 
care.
dIssEMInAtIOn
Our dissemination plan is designed to achieve maximum 
study exposure and impact among a range of beneficia-
ries (PwP and carers, healthcare professionals, national/
local decision makers, professional bodies, patient/carer 
organisations and the academic research community). 
Dissemination strategies will include presentations at a 
range of Parkinson’s disease/dementia/neurology and 
continence (bladder and bowel) related professional and 
research conferences. A final report will be submitted to 
Dunhill Medical Trust and Parkinson’s UK. A summary 
of the findings will be provided to all study participants 
(if requested). The main results paper will target a high- 
impact journal (eg, BMJ and Movement Disorders), while 
other papers (eg, methodology and health economics) 
will target relevant open access journals. Authorship and 
time scales will be agreed by the project management 
team. Findings will be provided to NICE and Cochrane 
Reviews for guideline updates for bladder and bowel 
dysfunction, diagnosis and management of Parkinson’s 
disease in primary and secondary care, local guidelines 
and care pathways and relevant Cochrane Reviews and 
updates. We will use Twitter to share study news and 
exploit other relevant social media to raise awareness of 
study progress and the findings, as well as press releases 
to news media.
Plans for communicating important protocol amendments to 
relevant parties (eg, trial participants and ethical committees)
Funders, sponsors and NHS Research & Develop-
ment Offices will be notified routinely and appropriate 
approvals gained and communicated as required by them 
and by the trial sponsor.
dIsCussIOn
This study is a pragmatic patient- oriented trial aiming to 
capture a true representation of the actual patient popu-
lation of interest. We know from previous work and from 
reviews that there is a lack of evidence- based interven-
tions for bladder dysfunction in PwP. The cost to the NHS 
and to the patient is considerable, and the effect on QOL 
both for patients and carers is significant and disabling. 
The lack of robust evidence on effective management 
leads to inconsistent advice and confused management 
pathways. Parkinson’s disease is a long- term condition, 
and supported self- management is important. TTNS as an 
adjunct to treatment offers a safe, non- invasive and non- 
drug intervention that can be undertaken by the patient 
or a carer at home. As such it is likely to be an attractive 
option for many. Should the trial demonstrate that TTNS 
is effective, we feel that an integration into standard local 
pathways should be possible, as the training required for 
clinicians and patients (or carers) is minimal.
trial status
Subject recruitment is underway. Currently 12 sites are 
recruiting, and we are ahead of target. The first partici-
pant was randomised in October 2018, and recruitment 
is due to end in June 2020. The TSC has met twice. The 
trial registration number is https:// doi. org/ 10. 1186/ 
ISRCTN12437878.
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